BioWorld: The Daily Biopharmaceutical and Medical Technology …
Daily news and analysis of the global biotechnology, pharmaceutical, and medical technology industries.
Duality Biologics reports preclinical findings with B7-H3/PD-L1 ...
Nov 8, 2024 · Duality Biologics Ltd. presented preclinical data on DB-1419, a potentially first-in-class bispecific antibody-drug conjugate (ADC) consisting of a humanized antibody targeting …
BB-203, a potentially best-in-class anti-PD-L1/anti-VEGF VHH …
Nov 22, 2024 · Bright Biologics LLC reported the discovery and preclinical evaluation of BB-203, an anti-PD-L1/anti-VEGF bispecific antibody (Ab) being developed for the treatment of cancer.
Financings for January 16, 2025 | BioWorld
Jan 16, 2025 · Med-tech firms raising money in public or private financings, including: GT Medical.
Rondo Therapeutics and Lilly partner on CD28 co-stimulatory …
Dec 5, 2024 · The collaboration will combine Rondo’s proprietary CD28 co-stimulatory platform with Lilly’s drug development and commercialization expertise to develop co-stimulatory …
Strong growth predicted for APAC med-tech market in 2025
Jan 2, 2025 · The Asia Pacific med-tech market is projected to reach $140 billion in 2025 in value, growing roughly 5% per year, driven largely by a rising demand for advanced and …
STAT6 stat sig? Kaken, J&J $1.2B-plus deal adds oomph to space
Jan 2, 2025 · Kaken Pharmaceutical Co. Ltd.’s license agreement with Johnson & Johnson (J&J) for signal transducer and activator of transcription (STAT)6 inhibitor KP-723 could …
Verdiva joins crowded GLP-1 space, launches with $411M series A
Jan 9, 2025 · New Anglo/U.S. obesity and cardiometabolic specialist Verdiva Bio Ltd. has launched with a massive $411 million series A and a portfolio of GLP-1 and amylin agonists in …
Zhongzhi drops $3M in Gabaeron series A for stem cell AD therapy
Jan 3, 2025 · Zhongzhi Pharmaceutical Holdings Ltd. made a $3 million investment in a series A financing round of stem cell therapy developer Gabaeron Inc. Dec. 21, expected to help propel …
Engineered yeast probiotics as carrier for GI tumor therapy
Dec 24, 2024 · Engineered probiotics, mainly bacterial probiotics, are an emerging platform for in situ delivery of therapeutics, including anticancer therapies, to the gut. Writing in Cell Chemical …